Novartis (NVS)
(Real Time Quote from BATS)
$99.17 USD
+0.82 (0.83%)
Updated Apr 25, 2024 03:44 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Novartis AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 8,572.00 | 6,955.00 | 24,018.00 | 8,071.00 | 7,147.00 |
Depreciation/Amortization & Depletion | 8,383.00 | 0.00 | 6,075.00 | 6,129.00 | 5,788.00 |
Net Change from Assets/Liabilities | -1,903.00 | -1,888.00 | -878.00 | -2,728.00 | 199.00 |
Net Cash from Discontinued Operations | 238.00 | 0.00 | 0.00 | 0.00 | 78.00 |
Other Operating Activities | -832.00 | 9,169.00 | -14,144.00 | 2,178.00 | 413.00 |
Net Cash From Operating Activities | 14,458.00 | 14,236.00 | 15,071.00 | 13,650.00 | 13,625.00 |
Property & Equipment | -823.00 | -1,031.00 | -1,138.00 | -1,187.00 | -522.00 |
Acquisition/ Disposition of Subsidiaries | -4,681.00 | -903.00 | 20,102.00 | -10,091.00 | -4,919.00 |
Investments | 10,838.00 | 4,674.00 | -13,854.00 | -915.00 | 3,177.00 |
Other Investing Activities | 262.00 | -1,272.00 | -902.00 | -989.00 | 38.00 |
Net Cash from Investing Activities | 5,596.00 | 1,468.00 | 4,208.00 | -13,182.00 | -2,226.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -8,566.00 | -10,552.00 | -3,057.00 | -2,094.00 | -5,533.00 |
Issuance (Repayment) of Debt | -2,223.00 | -2,559.00 | -2,146.00 | 5,123.00 | -3,102.00 |
Increase (Decrease) Short-Term Debt | 288.00 | 0.00 | -3,840.00 | 1,949.00 | -1,855.00 |
Payment of Dividends & Other Distributions | -7,255.00 | -7,506.00 | -7,368.00 | -6,987.00 | -6,645.00 |
Other Financing Activities | 3,478.00 | 55.00 | 147.00 | -199.00 | 3,508.00 |
Net Cash from Financing Activities | -14,278.00 | -20,562.00 | -16,264.00 | -2,208.00 | -13,627.00 |
Effect of Exchange Rate Changes | 100.00 | -32.00 | -266.00 | 286.00 | 69.00 |
Net Change In Cash & Equivalents | 5,876.00 | -4,890.00 | 2,749.00 | -1,454.00 | -2,159.00 |
Cash at Beginning of Period | 7,517.00 | 12,407.00 | 9,658.00 | 11,112.00 | 13,271.00 |
Cash at End of Period | 13,393.00 | 7,517.00 | 12,407.00 | 9,658.00 | 11,112.00 |
Diluted Net EPS | 7.10 | 3.17 | 10.63 | 3.52 | 5.06 |
Fiscal Year End for Novartis AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 8,572.00 | 5,934.00 | 4,611.00 | 2,294.00 |
Depreciation/Amortization & Depletion | NA | 8,383.00 | 6,758.00 | 3,896.00 | 2,043.00 |
Net Change from Assets/Liabilities | NA | -1,903.00 | -1,679.00 | -2,632.00 | -2,556.00 |
Net Cash from Discontinued Operations | NA | 238.00 | 238.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -832.00 | 660.00 | 658.00 | 1,176.00 |
Net Cash From Operating Activities | NA | 14,458.00 | 11,911.00 | 6,533.00 | 2,957.00 |
Property & Equipment | NA | -823.00 | -581.00 | -499.00 | -205.00 |
Acquisition/ Disposition of Subsidiaries | NA | -4,681.00 | -3,935.00 | -123.00 | -39.00 |
Investments | NA | 10,838.00 | 11,235.00 | 10,985.00 | 10,968.00 |
Other Investing Activities | NA | 262.00 | 637.00 | -795.00 | -103.00 |
Net Cash from Investing Activities | NA | 5,596.00 | 7,356.00 | 9,568.00 | 10,621.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -8,566.00 | -7,310.00 | -5,684.00 | -2,886.00 |
Issuance (Repayment) of Debt | NA | -2,223.00 | -2,223.00 | 6.00 | 2.00 |
Increase (Decrease) Short-Term Debt | NA | 288.00 | -322.00 | 161.00 | 947.00 |
Payment of Dividends & Other Distributions | NA | -7,255.00 | -7,255.00 | -7,255.00 | -7,255.00 |
Other Financing Activities | NA | 3,478.00 | 3,439.00 | -67.00 | -10.00 |
Net Cash from Financing Activities | NA | -14,278.00 | -13,671.00 | -12,839.00 | -9,202.00 |
Effect of Exchange Rate Changes | NA | 100.00 | -708.00 | 106.00 | 107.00 |
Net Change In Cash & Equivalents | NA | 5,876.00 | 4,888.00 | 3,368.00 | 4,483.00 |
Cash at Beginning of Period | NA | 7,517.00 | 7,517.00 | 7,517.00 | 7,517.00 |
Cash at End of Period | NA | 13,393.00 | 12,405.00 | 10,885.00 | 12,000.00 |
Diluted Net EPS | NA | 4.06 | 0.85 | 1.11 | 1.08 |